|Articles|November 1, 1997

November 1997
Volume 3
Issue 11

Cardiovascular Drug Prescribing Patterns: Where is the Evidence of Improvement?

Author(s)Sarah A. Spinler, PharmD

Download PDF: Cardiovascular Drug Prescribing Patterns: Where is the Evidence of Improvement?

Articles in this issue

over 28 years ago

Article

Empiric Examination of Physician Behavior in a Changing Healthcare Market

over 28 years ago

Article

Healthcare Utilization Among Women with Eating Disordered Behavior

over 28 years ago

Article

Postpartum Depression

over 28 years ago

Article

Pulmonary Rehabilitation: An Overview with Evidence for Its Utility in Chronic Obstructive Pulmonary Disease

over 28 years ago

Article

Pharmaceutical Considerations of Common Herbal Medicine

over 28 years ago

Article

When Is a Cost-Effectiveness Claim Valid? How Much Should the FDA Care?

over 28 years ago

Article

Treatment Patterns for Heart Failure in a Primary Care Environment

over 28 years ago

Article

Referrals to General Internists and Internal Medicine Trainees in an Academic Medicine Practice

over 28 years ago

Article

Enhancement of Compliance Among Patients with Hypertension

over 28 years ago

Article

Incorporating Quality of Life Data into Managed Care Formulary Decisions: A Case Study with Salmeterol

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Cardiovascular Drug Prescribing Patterns: Where is the Evidence of Improvement?

Articles in this issue

Related Content

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

Trending on AJMC

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD

SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD